Introduction: Little is known about the treatment response of bone lesions to treatment with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).
Aim(s): To compare the response of bone and soft tissue lesions to treatment with 177Lu-octreotate in patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs).
Materials and methods: Forty-two patients who: 1) had bone metastases that were positive on [111Indium-DTPA0]octreotide scintigraphy (SRS) before treatment; 2) had soft tissue lesions; and 3) had had a minimum of one follow-up CT, were studied. Lesions were scored on CT and bone lesions also on SRS before and after treatment.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Esther I. Van Vliet
To read results and conclusion, please login ...
Further abstracts you may be interested in